Quest Diagnostics Incorporated (NYSE:DGX) Files An 8-K Submission of Matters to a Vote of Security Holders

22

Quest Diagnostics Incorporated (NYSE:DGX) Files An 8-K Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders

(a) The following is a summary of the voting results for each
matter presented to the stockholders at the 2017 Annual Meeting
of Stockholders of Quest Diagnostics Incorporated (the
“Company”).
(b) The following nominees for the office of director were
elected for terms expiring at the 2018 Annual Meeting of
Stockholders, by the following votes:
For
Against
Abstain
Broker Non-Vote
Jenne K. Britell, Ph.D.
106,312,534
5,067,420
218,841
9,952,073
Vicky B. Gregg
108,676,223
2,750,392
172,183
9,952,070
Jeffrey M. Leiden, M.D., Ph.D.
108,448,707
2,813,269
336,821
9,952,071
Timothy L. Main
107,175,221
4,081,331
342,246
9,952,070
Gary M. Pfeiffer
105,412,335
5,856,327
330,136
9,952,070
Timothy M. Ring
103,212,338
8,045,782
340,678
9,952,070
Stephen H. Rusckowski
102,795,186
7,568,467
1,235,146
9,952,069
Daniel C. Stanzione, Ph.D.
102,001,423
8,027,809
1,569,567
9,952,069
Gail R. Wilensky, Ph.D.
103,441,455
6,704,598
1,452,745
9,952,070
(c) The advisory resolution to approve the executive officer
compensation disclosed in the Company’s 2017 Proxy Statement was
approved by the following votes:
For
Against
Abstain
Broker Non-Vote
102,318,798
8,815,048
464,762
9,952,260
(d) The holders of record of the number of shares indicated below,
all of which were entitled to vote at the Meeting, voted as follows
in respect of the frequency of the stockholder advisory vote to
approve executive officer compensation:
3 Years
2 Years
1 Year
Abstain
Broker Non-Vote
17,075,091
264,847
94,039,485
219,184
9,952,261
(e) The ratification of the appointment of the Company’s
independent registered public accounting firm for 2017 was
approved by the following votes:
For
Against
Abstain
116,502,215
4,895,916
152,737
(f) The amendments to the Company’s Amended and Restated
Long-Term Incentive Plan for Non-Employee Directors was approved
by the following votes:
For
Against
Abstain
Broker Non-Vote
87,049,100
24,191,716
357,793
9,952,259


About Quest Diagnostics Incorporated (NYSE:DGX)

Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, employers and others. The Company’s Diagnostic Solutions offers a range of solutions for insurers and healthcare providers. The Company provides risk assessment services for the life insurance industry. In addition, the Company offers healthcare organizations and clinicians’ health information technology solutions and diagnostic products. ExamOne provides risk assessment services to the life insurance industry in North America. ChartMaxx is the Company’s enterprise content management system for hospitals.

Quest Diagnostics Incorporated (NYSE:DGX) Recent Trading Information

Quest Diagnostics Incorporated (NYSE:DGX) closed its last trading session up +0.18 at 105.89 with 877,855 shares trading hands.

An ad to help with our costs